MustGrow to shut Canadian unit, shift focus to U.S. biofertility market

MustGrow Biologics will shut its Canadian distribution subsidiary NexusBioAg on April 15, moving away from a lower-margin resale business to focus on expanding sales of its TerraSante biofertility product in the U.S.

NexusBioAg, which distributed third-party agricultural inputs to Canadian farmers, operated in a price-competitive segment with limited margins. The remaining inventory will be sold through existing channels in the coming months.

MustGrow is redirecting capital toward increasing production of TerraSante after demand from large U.S. growers outpaced supply in 2025, a pattern has continued into this year.

The company raised $2 million in equity financing in January and secured an additional $2 million credit facility from the Canadian Imperial Bank of Commerce, backed by Export Development Canada, to support inventory build-up. It relies on third-party manufacturers, allowing it to scale output without investing in its own production facilities.

TerraSante, a mustard-derived organic product, is registered for sale in several U.S. states, including California and Florida, and is certified under OMRI and California’s Organic Input Material program.

MustGrow’s early data indicates the product may support soil conditions and crop performance. The company is also evaluating partnership opportunities to expand TerraSante into international markets, including through prior collaboration with Bayer AG.